98 related articles for article (PubMed ID: 15958556)
1. Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity.
Alvarez MJ; Prada F; Salvatierra E; Bravo AI; Lutzky VP; Carbone C; Pitossi FJ; Chuluyan HE; Podhajcer OL
Cancer Res; 2005 Jun; 65(12):5123-32. PubMed ID: 15958556
[TBL] [Abstract][Full Text] [Related]
2. Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction.
Horie K; Tsuchihara M; Nakatsura T
Cancer Sci; 2010 Apr; 101(4):913-9. PubMed ID: 20100207
[TBL] [Abstract][Full Text] [Related]
3. Preconditioned endothelial progenitor cells reduce formation of melanoma metastases through SPARC-driven cell-cell interactions and endocytosis.
Defresne F; Bouzin C; Grandjean M; Dieu M; Raes M; Hatzopoulos AK; Kupatt C; Feron O
Cancer Res; 2011 Jul; 71(14):4748-57. PubMed ID: 21616936
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells.
Sosa MS; Girotti MR; Salvatierra E; Prada F; de Olmo JA; Gallango SJ; Albar JP; Podhajcer OL; Llera AS
Proteomics; 2007 Nov; 7(22):4123-34. PubMed ID: 17994631
[TBL] [Abstract][Full Text] [Related]
5. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
6. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
7. The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression.
Fenouille N; Robert G; Tichet M; Puissant A; Dufies M; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S
Pigment Cell Melanoma Res; 2011 Feb; 24(1):219-32. PubMed ID: 20955243
[TBL] [Abstract][Full Text] [Related]
8. [The role of SPARC gene in tumorigenic capacity of human melanoma cells].
Ledda MF; Adris S; Bover L; Bravo AL; Mordoh J; Podhajcer OL
Medicina (B Aires); 1996; 56(1):51-4. PubMed ID: 8734932
[TBL] [Abstract][Full Text] [Related]
9. SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated.
Haber CL; Gottifredi V; Llera AS; Salvatierra E; Prada F; Alonso L; Sage EH; Podhajcer OL
Int J Cancer; 2008 Apr; 122(7):1465-75. PubMed ID: 18059024
[TBL] [Abstract][Full Text] [Related]
10. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates.
Cho D; Song H; Kim YM; Houh D; Hur DY; Park H; Yoon D; Pyun KH; Lee WJ; Kurimoto M; Kim YB; Kim YS; Choi I
Cancer Res; 2000 May; 60(10):2703-9. PubMed ID: 10825144
[TBL] [Abstract][Full Text] [Related]
11. Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice.
Ikuta Y; Hayashida Y; Hirata S; Irie A; Senju S; Kubo T; Nakatsura T; Monji M; Sasaki Y; Baba H; Nishimura Y
Cancer Sci; 2009 Jan; 100(1):132-7. PubMed ID: 19068096
[TBL] [Abstract][Full Text] [Related]
12. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
[TBL] [Abstract][Full Text] [Related]
13. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
14. T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells.
Tada Y; O-Wang J; Takiguchi Y; Tatsumi K; Kuriyama T; Tagawa M
Int J Mol Med; 2002 Mar; 9(3):281-5. PubMed ID: 11836634
[TBL] [Abstract][Full Text] [Related]
15. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice.
Mrowietz U; Schwenk U; Maune S; Bartels J; Küpper M; Fichtner I; Schröder JM; Schadendorf D
Br J Cancer; 1999 Mar; 79(7-8):1025-31. PubMed ID: 10098731
[TBL] [Abstract][Full Text] [Related]
16. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth.
Prada F; Benedetti LG; Bravo AI; Alvarez MJ; Carbone C; Podhajcer OL
J Invest Dermatol; 2007 Nov; 127(11):2618-28. PubMed ID: 17625595
[TBL] [Abstract][Full Text] [Related]
17. Human Fas-ligand expression on porcine endothelial cells does not protect against xenogeneic natural killer cytotoxicity.
Matter-Reissmann UB; Sonntag KC; Gilli UO; Leguern C; Schneider MK; Seebach JD
Xenotransplantation; 2004 Jan; 11(1):43-52. PubMed ID: 14962292
[TBL] [Abstract][Full Text] [Related]
18. Loss of insulin-like growth factor I receptor-dependent expression of p107 and cyclin A in cells that lack the extracellular matrix protein secreted protein acidic and rich in cysteine.
Basu A; Rodeck U; Prendergast GC; Howe CC
Cell Growth Differ; 1999 Nov; 10(11):721-8. PubMed ID: 10593648
[TBL] [Abstract][Full Text] [Related]
19. SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation.
Maloney SC; Marshall JC; Antecka E; Orellana ME; Fernandes BF; Martins C; Castiglione E; DI Cesare S; Logan P; Burnier MN
Anticancer Res; 2009 Aug; 29(8):3059-64. PubMed ID: 19661316
[TBL] [Abstract][Full Text] [Related]
20. SPARC enhances tumor stroma formation and prevents fibroblast activation.
Chlenski A; Guerrero LJ; Yang Q; Tian Y; Peddinti R; Salwen HR; Cohn SL
Oncogene; 2007 Jul; 26(31):4513-22. PubMed ID: 17260013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
